Q3 2024 Catalyst Pharmaceuticals Inc Earnings Call Transcript
Key Points
- Catalyst Pharmaceuticals Inc (CPRX) reported a 25.3% year-over-year increase in total revenues for Q3 2024, reaching $128.7 million.
- The company updated its full-year 2024 total revenue guidance to between $475 million and $485 million, reflecting strong performance.
- Ferds continues to deliver outstanding net revenues and growth, with a 19.7% increase year-over-year.
- A gaming's market success led to an increase in full-year 2024 net revenue projections to between $40 million and $45 million.
- Catalyst Pharmaceuticals Inc (CPRX) is making strides in global expansion, with recent regulatory approval in Japan and ongoing efforts in Canada.
- Capa experienced a 12% decrease in net revenues compared to Q3 2023 due to adjustments in gross to net.
- Increased gross to net deductions for Pampa were driven by higher costs tied to arrangements with distributors and government agencies.
- The company faces competitive challenges in the market, particularly with the launch of a gaming into an active competitive environment.
- Research and development expenses are expected to be significantly lower than previously provided guidance, indicating potential delays in R&D initiatives.
- The effective tax rate is likely to fluctuate in future periods, affecting financial predictability.
Thank you for standing by. My name is Chris and I will be your conference operator today. At this time, I would like to welcome everyone to the Catalyst Pharmaceuticals third quarter, 2024 financial results conference call lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to withdraw your question. Press star one again. Thank you. I would now like to turn the call over to my CFO. Please go ahead.
Thank you. Good morning everyone and thank you for joining our conference call to discuss Catalyst Pharmaceuticals third quarter, 2024 financial results and business highlights Rich Daly President and CEO will lead the call today. And Jeff Del Carmen, our Chief Commercial Officer and I will also present additionally, Dr Steve Miller, our Chief Operating Officer and Chief
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
